Novel menadione hybrids: Synthesis, anticancer activity, and cell-based studies

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Cancer Biology

Background:

• Menadione derivatives are explored for anticancer properties.
• Triazole hybrids offer diverse pharmacological activities.
• Copper-catalyzed azide-alkyne cycloaddition (CuAAC) is a versatile synthetic tool.

Purpose of the Study:

• To design and synthesize novel menadione-based triazole hybrids.
• To evaluate the in vitro anticancer potential of these hybrids against various cancer cell lines.
• To investigate the mechanism of action of the most potent compound.

Main Methods:

• Synthesis of menadione-triazole hybrids via CuAAC.
• Characterization using NMR, IR, and HRMS.
• Anticancer activity evaluation using MTT assay.
• Cell cycle analysis, Hoechst staining, mitochondrial membrane potential, and Annexin-V-FITC assays.

Main Results:

• Majority of synthesized hybrids exhibited significant anticancer activity.
• Compounds 5 and 6 demonstrated potent activity across all tested cancer cell lines.
• Compound 6 showed superior efficacy compared to tamoxifen and menadione against MCF-7 cells.
• Compound 6 induced G0/G1 cell cycle arrest and apoptosis.

Conclusions:

• Menadione-triazole hybrids are promising anticancer agents.
• Compound 6 is a potent lead molecule for anticancer drug development.
• Further investigation into compound 6's mechanism and therapeutic potential is warranted.